BF
RARE icon

BOK Financial’s Ultragenyx Pharmaceutical RARE Stock Holding History

BOK Financial’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-34
Closed -$1.23K – 1298
2025
Q1 		$1.23K Sell
34
-7,942
-100% -$330K ﹤0.01% 1160
2024
Q4 		$336K Buy
7,976
+382
+5% +$19K 0.01% 621
2024
Q3 		$407K Sell
7,594
-722
-9% -$36.8K 0.01% 604
2024
Q2 		$342K Buy
8,316
+1,580
+23% +$67.5K 0.01% 669
2024
Q1 		$316K Buy
+6,736
New +$318K 0.01% 629
2020
Q1 		– Sell
-13,188
Closed -$563K – 904
2019
Q4 		$563K Buy
+13,188
New +$544K 0.01% 675

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return